Enlivex Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 16, 2026, disclosing a securities purchase agreement for a registered direct offering of up to $7,500,000 in ordinary shares and accompanying warrants.

Key Highlights

  • Offering size: Aggregate gross proceeds expected to be approximately $7.5 million, assuming all closings are consummated, before deducting offering expenses and excluding any proceeds from warrant exercises.
  • Combined purchase price: $1.315 per ordinary share (or $1.314 per pre-funded warrant) with accompanying ordinary warrant, representing a premium of 10.5% to the Nasdaq official closing price on November 13, 2026.
  • Structured closings: An initial closing of $500,000 expected on or about November 17, 2026, followed by 10 subsequent monthly closings of $700,000 each, commencing December 1, 2026 and ending on or about September 1, 2027.
  • Ordinary warrant terms: Exercise price of $1.578 per ordinary share, exercisable immediately upon issuance, expiring three years from the initial closing date.
  • Pre-funded warrant terms: Exercise price of $0.001 per ordinary share, exercisable immediately upon issuance, with no expiration until exercised in full.
  • Revenue participation: Certain investors meeting a minimum subscription threshold are entitled to 5% of specified commercial transaction payments and 5% of proceeds from any sale or exclusive license of clinical assets during defined periods, subject to conditions.
  • Payment flexibility: The purchase price may be paid in U.S. dollars, Tether (USDT), or a combination thereof.

Enlivex Discloses Multi-Tranche Securities Purchase Agreement Terms

According to the filing, Enlivex Ltd. entered into a securities purchase agreement on November 14, 2026, with certain investors for the purchase and sale, in a registered direct offering, of ordinary shares with par value NIS 96.00 per share (or pre-funded warrants in lieu thereof), together with accompanying ordinary warrants. The securities are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-286956), which the filing states became effective on May 12, 2025.

The registered offering is structured as a series of closings. The filing discloses that investors have irrevocably committed, subject only to the continued listing of the ordinary shares on Nasdaq or another U.S. national securities exchange, to fund $700,000 at each of 10 subsequent monthly closings after the initial $500,000 closing. The filing notes that certain subsequent closings may be postponed pending shareholder approval of an increase in authorized share capital, and any subsequent closing may be postponed if the company's registration statement or prospectus is not then available.

The filing further discloses a revenue participation arrangement. Investors meeting a minimum subscription threshold of $850,000 are entitled to receive 5% of upfront payments, milestone payments, and royalties from specified commercial transactions entered into during a defined 24-month window, as well as 5% of proceeds from any sale, exclusive license, or other disposition of the company's clinical assets during that same period. An investor's right to receive such payments will be forfeited, according to the filing, if it fails to fund at least $850,000 of the aggregate subscription amount. The filing was signed by Oren Hershkovitz, Chief Executive Officer, on November 16, 2026, and the company issued a press release on the same date announcing the registered offering.

What Was Disclosed

Enlivex Ltd. disclosed a securities purchase agreement for a $7.5 million registered direct offering structured across 11 closings from November 2026 through approximately September 2027, including warrant terms, pricing details, a revenue participation arrangement for qualifying investors, and an option to pay in USDT.